BioSpace News Archive

Tenax Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Company’s Investigational New Drug (IND) Application for TNX-103 (oral levosimendan) for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF), enabling Tenax to proceed with the first of two Phase 3 studies.

Legend Biotech Corporation announced today that Legend Biotech Ireland Limited, a wholly owned subsidiary of Legend Biotech, has entered into an exclusive, global license agreement (License Agreement) with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102 (NCT05680922).

Sunshine Biopharma Inc. today announced that it has filed its quarterly report for the 2023 third quarter.

Galectin Therapeutics, Inc. reported financial results and provided a business update for the three months ended September 30, 2023.

Neuronetics, Inc. announced significant updates to the NeuroStar software and TrakStar® Patient Data Management System, a proprietary, HIPAA-compliant, patient management and outcomes reporting system for NeuroStar providers.

Iridex Corporation announced the Company will host its third quarter financial results conference call on November 14, 2023 and plans to participate in the upcoming Stifel Healthcare Conference on November 15, 2023 in New York, NY.

Abbott announced new late-breaking data that show advanced heart failure patients living with its HeartMate 3™ heart pump who didn’t receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant.

Aether Biomedical, a biotech company creating cutting-edge bionic prosthetics, announced the successful conclusion of a $5.8 Million Series A funding round, led by J2 Ventures and Story Ventures.

Inflammasome Therapeutics (https://inflam.com), a private company, developing a new class of inflammasome inhibitor drugs called Kamuvudines as therapies for prevalent, degenerative diseases, announced the FDA has granted approval for the opening of a Phase 1/2 clinical trial of the company’s drug for the treatment of Geographic Atrophy (GA), the most severe form of dry AMD.

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announced the close of a €129 million Series A financing to advance its vectorized antibody programs in neurodegenerative diseases.